Bank of America
EGRX

Bank of America’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bank of America’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-51,006
Closed -$190K – 8596
2024
Q3 		$190K Sell
51,006
-274,513
-84% -$1.31M ﹤0.01% 6016
2024
Q2 		$1.82M Buy
325,519
+15
+0% +$65 ﹤0.01% 4506
2024
Q1 		$1.71M Buy
325,504
+138,546
+74% +$760K ﹤0.01% 4547
2023
Q4 		$978K Buy
186,958
+182,239
+3,862% +$1.8M ﹤0.01% 4999
2023
Q3 		$74.4K Sell
4,719
-8,115
-63% -$146K ﹤0.01% 6370
2023
Q2 		$249K Sell
12,834
-305,340
-96% -$7.24M ﹤0.01% 5696
2023
Q1 		$9.03M Buy
318,174
+277,192
+676% +$8.23M ﹤0.01% 2931
2022
Q4 		$1.2M Buy
40,982
+5,442
+15% +$173K ﹤0.01% 4692
2022
Q3 		$939K Buy
35,540
+32,252
+981% +$1.18M ﹤0.01% 4947
2022
Q2 		$146K Sell
3,288
-1,072
-25% -$49.2K ﹤0.01% 6294
2022
Q1 		$215K Sell
4,360
-88,332
-95% -$4.24M ﹤0.01% 6418
2021
Q4 		$4.72M Buy
92,692
+28,873
+45% +$1.5M ﹤0.01% 3707
2021
Q3 		$3.56M Buy
63,819
+3,376
+6% +$166K ﹤0.01% 3899
2021
Q2 		$2.59M Sell
60,443
-5,069
-8% -$209K ﹤0.01% 4108
2021
Q1 		$2.73M Sell
65,512
-1,916
-3% -$89K ﹤0.01% 3969
2020
Q4 		$3.14M Sell
67,428
-47,634
-41% -$2.23M ﹤0.01% 3555
2020
Q3 		$4.89M Buy
115,062
+41,600
+57% +$1.82M ﹤0.01% 2931
2020
Q2 		$3.52M Sell
73,462
-10,182
-12% -$508K ﹤0.01% 3165
2020
Q1 		$3.85M Sell
83,644
-614
-0.7% -$30.8K ﹤0.01% 2908
2019
Q4 		$5.06M Sell
84,258
-36,111
-30% -$2.15M ﹤0.01% 3234
2019
Q3 		$6.81M Buy
120,369
+24,641
+26% +$1.39M ﹤0.01% 2902
2019
Q2 		$5.33M Sell
95,728
-39,394
-29% -$2.05M ﹤0.01% 3171
2019
Q1 		$6.82M Buy
135,122
+59,092
+78% +$2.63M ﹤0.01% 2847
2018
Q4 		$3.06M Buy
76,030
+23,121
+44% +$1.19M ﹤0.01% 3484
2018
Q3 		$3.67M Sell
52,909
-17,924
-25% -$1.36M ﹤0.01% 3481
2018
Q2 		$5.36M Buy
70,833
+45,857
+184% +$2.88M ﹤0.01% 3087
2018
Q1 		$1.32M Sell
24,976
-4,293
-15% -$250K ﹤0.01% 4192
2017
Q4 		$1.56M Sell
29,269
-9,516
-25% -$530K ﹤0.01% 4154
2017
Q3 		$2.31M Buy
38,785
+18,429
+91% +$1.11M ﹤0.01% 3864
2017
Q2 		$1.61M Buy
20,356
+5,591
+38% +$457K ﹤0.01% 4078
2017
Q1 		$1.23M Buy
14,765
+334
+2% +$24.8K ﹤0.01% 4285
2016
Q4 		$1.15M Buy
14,431
+12,808
+789% +$930K ﹤0.01% 4237
2016
Q3 		$113K Sell
1,623
-1,328
-45% -$73.6K ﹤0.01% 5380
2016
Q2 		$115K Buy
2,951
+2,627
+811% +$109K ﹤0.01% 5453
2016
Q1 		$13K Sell
324
-8,498
-96% -$539K ﹤0.01% 6305
2015
Q4 		$783K Buy
8,822
+8,182
+1,278% +$646K ﹤0.01% 4519
2015
Q3 		$47K Sell
640
-7,138
-92% -$594K ﹤0.01% 5969
2015
Q2 		$629K Buy
+7,778
New +$507K ﹤0.01% 4518
2014
Q3 		– Sell
-12,076
Closed -$173K – 8212
2014
Q2 		$173K Buy
+12,076
New +$138K ﹤0.01% 5678

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $508M AUM 24.82% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Bank of America's EGRX Position: Q4 2024 in Review

Bank of America sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 51,006 shares — an estimated $190K sold.

Bank of America first reported a position in EGRX in Q2 2014 and held it in 39 quarters. The position peaked at $9.03M in Q1 2023. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Bank of America reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Bank of America sold 51,006 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $190K.
  • Bank of America first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and held it in 39 quarters.
  • Bank of America's Eagle Pharmaceuticals, Inc. position peaked at $9.03M in Q1 2023.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Bank of America's 13F filing for Q4 2024, filed 14 Feb 2025.